New stroke drug aleeto enters human trials – could it limit brain damage?
NCT ID NCT06759753
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests whether the drug Aleeto can improve neurological function in people who have had a moderate to severe ischemic stroke. About 192 participants will receive either Aleeto or a placebo by IV within 72 hours of their stroke. The main goal is to see if Aleeto leads to better recovery scores on the NIH Stroke Scale at 14 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aleeto (intravenous injection)
- What this could lead to
- If it works, this could point toward a new treatment to reduce brain damage and improve recovery after a moderate to severe stroke.
- What could go wrong
- This is an early Phase 2 trial with only 192 people, so results may not apply to all stroke patients. The drug may not show meaningful benefit over placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tiantan Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?